The introduction of anti-HER2 monoclonal antibodies (e.g., trastuzumab, pertuzumab) back in the 90 s revolutionized the treatment landscape of HER2+ breast cancer, drastically improving the life expectations of these patients (Dieci and Miglietta 2021). This evidence concerns the gene ERBB2 and breast carcinoma.